
We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
To own National Health Investors, you need to be comfortable with a REIT story anchored in senior housing demand and the execution of its SHOP growth plan, while accepting tenant and operating risk. The broad removal from Russell growth indices may influence short term trading flows, but it does not appear to change the core near term catalyst around stabilizing occupancy in the SHOP portfolio or the key risks around tenant concentration and funding growth.
Against this backdrop, NHI’s March 2026 filing for up to US$500,000,000 in follow on equity is particularly relevant, as it can shape how the company finances future senior housing investments while balancing dilution risk. How effectively NHI deploys any new capital into occupancy supporting assets, and integrates acquisitions without disrupting cash flows, sits right alongside index changes in the minds of many shareholders.
Yet beneath the index reshuffle, investors should also be aware of how concentrated tenant exposure could...
Read the full narrative on National Health Investors (it's free!)
National Health Investors’ narrative projects $546.5 million revenue and $198.5 million earnings by 2029.
Uncover how National Health Investors' forecasts yield a $85.75 fair value, a 11% upside to its current price.
Four members of the Simply Wall St Community value NHI between US$66.50 and US$175.26 per share, showing a wide span of expectations. You can weigh those views against current concerns about SHOP occupancy softness and consider what that might mean for future cash flows.
Explore 4 other fair value estimates on National Health Investors - why the stock might be worth over 2x more than the current price!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com